Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

AstraZeneca PLC (AZN)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
36,760.500 +595.000    +1.65%
15/04 - Closed. Currency in ARS ( Disclaimer )
  • Volume: 750
  • Bid/Ask: 36,760.500 / 36,957.000
  • Day's Range: 36,240.500 - 37,189.500
Type:  Equity
Market:  Argentina
ISIN:  ARDEUT112489 
AstraZeneca 36,760.500 +595.000 +1.65%

AZN Financial Summary

 
A brief financial summary of AstraZeneca PLC as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

AstraZeneca PLC reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 1,428 million compared to USD 755 million a year ago. Revenue was USD 45,811 million compared to USD 44,351 million a year ago. Net income was USD 5,955 million compared to USD 3,288 million a year ago. Basic earnings per share from continuing operations was USD 3.84 compared to USD 2.12 a year ago. Diluted earnings per share from continuing operations was USD 3.81 compared to USD 2.11 a year ago.

AnnualQuarterly  
InvestingPro Advanced Financial Summary
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

AZN Income Statement

Gross margin TTM 82.45%
Operating margin TTM 22.78%
Net Profit margin TTM 13%
Return on Investment TTM 12.49%
 Total Revenue  Net Income
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Revenue 12024 11492 11416 10879
Gross Profit 9729 9437 9499 9106
Operating Income 2034 2533 2602 2687
Net Income 960 1374 1818 1803

AZN Balance Sheet

Quick Ratio MRQ 0.47
Current Ratio MRQ 0.82
LT Debt to Equity MRQ 57.23%
Total Debt to Equity MRQ 75.75%
 Total Assets  Total Liabilities
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Total Assets 101119 96086 96543 96687
Total Liabilities 61953 58865 59127 60876
Total Equity 39166 37221 37416 35811

AZN Cash Flow Statement

Cash Flow/Share TTM 6.67
Revenue/Share TTM 29.56
Operating Cash Flow  7.79%
 Cash  Net Change in Cash
Period Ending: Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023
Period Length: 0 Months 0 Months 0 Months 0 Months
Cash From Operating Activities 2380 3114 1718 3133
Cash From Investing Activities -1077 -1221 -520 -1246
Cash From Financing Activities -291 -2726 -1519 -2031
Net Change in Cash 1018 -852 -357 -155
* In Millions of USD (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

AZN Comments

Write your thoughts about AstraZeneca PLC
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Oct 28, 2021 0:25
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Double top in reach
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email